Plant-Based Vaccines Market Size, Share, Growth and Forecast, 2025-2035

Plant-made vaccine revenue rebuilds after Medicago's exit

The plant-based vaccines market was valued at USD 36.4 million in 2025 and is projected to increase from USD 43.5 million in 2026 to USD 216.1 million by 2035, registering a CAGR of 19.50% during 2025–2035. Demand rests on the speed of leaf-based antigen production, government funding for pandemic-ready capacity and licensed animal vaccines, led by a plant-derived classical swine fever vaccine in South Korea. Asia Pacific held the largest regional share, 36.8% in 2025, on Korean swine vaccine sales and contract work in Thailand. The main commercial change is a reset, because no plant-made human vaccine was on sale in 2025 after Medicago closed in 2023, and the field now waits on a 728-participant Phase 1/2 seasonal flu trial that Aramis Biotechnologies began in February 2026.

What counts as a plant-based vaccine and who pays for it

The market counts money paid for vaccines and vaccine antigens produced in whole plants or plant cell cultures, for people or animals. It includes licensed product sales, today almost entirely veterinary; fees paid to plant-platform service providers to express, purify and supply antigens; and government and partner payments for specific vaccine programs, the largest single pool in 2025.

It excludes plant-made antibodies, enzymes and other therapeutic proteins, vaccines made in yeast, insect, bacterial or mammalian cells, plant-derived adjuvants sold to conventional vaccine makers and basic research grants that buy no services.

Leaf expression, drug developers and swine subunits lead

Transient expression leads the technology mix and grows fastest

Based on technology, the market is categorized into transient expression systems, stable transformation and plant cell cultures. Transient expression systems led with 70.3% of 2025 value, because the antigen gene is delivered into leaves for a single production run and a new strain needs only a new gene sequence. The same technology grows fastest at 21.01% a year, since Aramis, Leaf Expression Systems, Kentucky BioProcessing and Baiya Phytopharm all build their programs on it.

Drug developers pay the most among end users and increase spending fastest

Based on end-user, the market is categorized into pharmaceutical and biotechnology companies, government agencies, animal health companies and academic and research institutions. Pharmaceutical and biotechnology companies led with 41.2% of 2025 value, paying for antigen development, clinical supply and outsourced sterile steps. They also grow fastest at 23.22% a year as development spending moves toward late-stage trials, while public funding tends to arrive in waves after health emergencies.

Subunit vaccines lead product types while VLP vaccines grow fastest

Based on product type, the market is categorized into subunit vaccines, virus-like particle (VLP) vaccines and other plant-derived vaccines, including oral and experimental formats. Subunit vaccines led with 46.2% of 2025 value, driven by licensed swine fever marker vaccine sales in South Korea. VLP vaccines grow fastest at 22.85% a year, mainly on the strength of the Aramis seasonal influenza program, which builds on the former Medicago VLP platform.

Fast antigen output, pandemic funding and swine demand

Leaf expression produces a new antigen within days

In a transient expression system, a gene for the target antigen is delivered into leaves of a fast-growing tobacco relative, and the plant makes the protein within days. No virus is grown in eggs or cell tanks, and a new influenza strain needs only a new gene sequence. Leaf Expression Systems licenses its Hypertrans system from the John Innes Centre for vaccines, antibodies and enzymes, and Aramis, Kentucky BioProcessing and Baiya Phytopharm build their own programs on the same method for seasonal flu and outbreak response. That speed is why transient expression grows fastest among technologies through 2035.

Governments fund plant platforms as pandemic insurance

Governments see plant platforms as capacity that can switch to a new antigen without a new factory. On Dec. 5, 2024, the Government of Canada announced a Strategic Innovation Fund investment in Aramis Biotechnologies to optimize its plant-based manufacturing process and take a next-generation seasonal flu vaccine through Phase 2. Public money of this kind is the largest single revenue pool today and helps make North America the fastest-growing region.

Download Free Sample

Swine marker vaccines give plant platforms a commercial foothold

BioApp of Pohang, South Korea, received approval in April 2019 for HERBAVAC CSF Green Marker, described by pig333 as the first plant-derived recombinant subunit vaccine against classical swine fever. It carries the E2 antigen but not the Erns antigen of field virus, so vets can tell vaccinated pigs from infected ones. South Korea began 2025 with about 10.8 million pigs, according to USDA data. That herd underpins licensed product sales, which is why subunit vaccines led product types and why Korean swine sales put Asia Pacific ahead of North America in 2025.

Contract capacity is being rebuilt in Norwich, Bangkok and Texas

Leaf Expression Systems runs a purpose-built plant on Norwich Research Park with growing rooms and protein purification. In Bangkok, Baiya Phytopharm runs what it calls the first cGMP plant-based facility in Asia and sells contract services through Molecular Pharming Solution. In June 2024, the Texas A&M University System acquired iBio's former plant in Bryan, Texas, according to an SEC filing. Contract and development spending bridges the gap to product revenue.

Closed growing rooms and outsourced fill-finish emerge

Production shifts from greenhouses to closed growing rooms

In June 2025, Aramis said it had replaced traditional greenhouses with a proprietary closed, controlled-environment production system and achieved a multifold rise in plant protein productivity. Consistent biomass is the hardest part of plant manufacturing to prove to a regulator, so Credence Research expects closed systems to become the norm for human vaccine work by 2030. In July 2026, Aramis also launched a study with CIRAIG, Premier Tech and CRIBIQ on the environmental footprint of plant bioproduction.

Plant developers outsource sterile fill-finish

Small developers keep antigen expression in-house and buy the sterile steps. Aramis announced a partnership with the non-profit Biologics Manufacturing Centre in February 2025, and on Feb. 10, 2026, the two completed formulation, aseptic fill-finish and clinical packaging of the flu candidate, according to BIOTECanada. The same split is common across vaccine contract manufacturing, and it lets plant developers reach the clinic without building their own sterile lines.

Download Free Sample

A plant-made flu vaccine for adults 65 and over offers an opportunity

Aramis Biotechnologies began a randomized Phase 1/2 trial of its trivalent, plant-made seasonal influenza vaccine on Feb. 26, 2026, enrolling 728 healthy volunteers at seven sites across Canada and comparing it with commercial vaccines for adults aged 18 to 64 and 65 and over. Older-adult flu shots are a large, repeat purchase, so VLP vaccines stand to grow fastest among product types if the data hold.

Marker subunit vaccines for the largest pig herds open an opportunity

Marker vaccines that tell infection from vaccination support eradication programs and export status, which live attenuated vaccines cannot. USDA data show China began 2025 with about 427.4 million pigs, the European Union 132.1 million, the United States 75.1 million and Brazil 34.1 million. Plant-made subunits face a shorter, cheaper approval path than human vaccines, so swine and poultry antigens offer near-term product revenue for platform owners while human programs mature.

Medicago's exit, batch consistency and a thin pipeline

Medicago's closure showed an authorized vaccine is not a business

Medicago's Covifenz became the first COVID-19 vaccine using plant-based protein technology when the Health Canada authorized it on Feb. 24, 2022, for adults aged 18 to 64, after trials showed 71% efficacy against symptomatic infection. In February 2023, Mitsubishi Chemical Group began winding Medicago down, citing reduced demand for COVID-19 vaccines and scale-up challenges. Investors now ask who buys and whether supply is reliable, so developers target repeat-purchase vaccines such as seasonal flu.

Batch consistency remains the main scale-up risk

Plant biomass varies with light, temperature and handling, and each batch has to match the last for regulators. Aramis says its clinical-scale, GMP-compliant process is already enough for a commercial launch without further scale-up. Credence Research treats that as a claim to be proven in Phase 3 and commercial supply, not a settled fact. Closed growing rooms, tighter process controls and outsourced sterile steps are the main ways developers reduce the risk before filing.

A second human approval is unlikely before 2030

The only active human program Credence Research tracks toward late-stage development is a Phase 1/2 flu trial that began in 2026. Allowing for Phase 3 and regulatory review, Credence Research does not expect a plant-made human vaccine on sale before 2030, so product revenue stays small for half of the forecast period. Developers bridge the gap with contract work, animal vaccines and public funding, but each delay pushes revenue and investor patience further out.

Platform owners divert plant capacity to antibodies and other proteins

iBio's sale of its Bryan plant completed a shift toward antibody discovery, Kentucky BioProcessing describes a pipeline of antibodies and vaccines, and Baiya sells growth factors through BGF Plantrix. That diversification keeps facilities busy but thins the vaccine pipeline. History also adds caution, because the USDA approved a Dow AgroSciences plant-cell vaccine production system in 2006, yet no large plant-cell vaccine line followed. Clear late-stage data and dedicated vaccine funding are the main remedy.

Korean swine sales edge Asia Pacific past North America

Asia Pacific leads on Korean swine vaccine sales and Thai contract services

Asia Pacific held 36.8% of 2025 value and grows at 19.80% a year. Licensed swine fever vaccine sales by BioApp in South Korea and contract and development work at Baiya Phytopharm in Thailand make up most of it. Baiya signed a memorandum of understanding with Japan's KAICO on protein expression services in October 2025. Its PIC/S-compliant site gives regional governments a route to domestic vaccine capacity without a large mammalian-cell plant.

North America relies on Canada for the human vaccine pipeline

North America held 36.3% of 2025 value and is the fastest-growing region at 21.50% a year. Canada carries the human vaccine pipeline through Aramis, which launched in December 2023 with Medicago's research assets and pilot facility in Quebec City. The United States hosts Kentucky BioProcessing and the former iBio plant now owned by Texas A&M. A first approval of a plant-made flu vaccine would most likely land in this region first.

Download Free Sample

Europe earns from contract expression rather than product sales

Europe held 20.3% of 2025 value and grows at 15.20% a year. The United Kingdom's Leaf Expression Systems is the main contract provider, backed by plant science at the John Innes Centre. Credence Research sees little human vaccine product revenue in the region before 2035. Large pig herds in the European Union offer a later opening for plant-made marker vaccines once developers secure veterinary registrations country by country across the bloc.

Latin America has large pig and poultry sectors that await registrations

Latin America held 4.1% of 2025 value and grows at 18.40% a year. Large pig and poultry sectors in Brazil, Mexico and Argentina make the region a natural market for plant-made animal vaccines once local registrations clear.

Middle East & Africa builds research partnerships and long-run manufacturing plans

The Middle East & Africa held 2.5% of 2025 value and grows at 14.10% a year. Demand today is limited to research partnerships, while regional vaccine-manufacturing plans give plant platforms a long-run opening.

Download Free Sample

A Canadian flu trial, public funding and asset transfers

Leaf expression, controlled growing and marker antigens

• Transient expression delivers genes into leaves of a tobacco relative and yields antigen within days, suited to seasonal flu and outbreak response.
• Controlled growing in closed, controlled-environment rooms replaces greenhouses to keep biomass and antigen yield consistent from batch to batch.
• VLP antigens are plant-made virus-like particles that mimic a virus shell without genetic material, the basis of the former Medicago platform and the Aramis flu candidate.
• Marker subunits, subunit antigens such as E2 without Erns, let vets separate vaccinated from infected animals, supporting eradication and trade.
• Outsourced sterile steps such as formulation and aseptic fill-finish at partners like the Biologics Manufacturing Centre cut capital needs for small developers.

Few platform developers and contract providers compete

Few companies compete in plant-based vaccines, and most are small. Developers with their own programs include Aramis Biotechnologies, which runs the only active human trial Credence Research tracks, Kentucky BioProcessing and Baiya Phytopharm, which has a plant-made COVID-19 candidate in Phase 1. Contract providers include Leaf Expression Systems, which holds rights to sublicense the Hypertrans system, and Baiya's Molecular Pharming Solution. The Biologics Manufacturing Centre is not a plant platform but performs sterile fill-finish for plant-made candidates. BioApp owns the clearest licensed product, while Medicago, iBio and Dow AgroSciences have left vaccine production. Credence Research estimates that the 5 largest participants hold well over half of 2025 value, because the cost of running GMP plant facilities without product revenue keeps entrants out.

Plant vaccine developers, service providers and former players

One approved flu vaccine would reset the plant business

Credence Research's view is that plant-based vaccines remain a platform waiting for its second approved human product, and that a successful plant-made flu vaccine for older adults would reset investor interest more than any funding round. Until then, licensed swine marker vaccines, contract services and public programs carry the market. The main risk is another commercial failure after approval, as happened with Medicago. Investors should watch the Aramis Phase 1/2 readout, batch consistency data and new veterinary registrations in Asia and Latin America.

Revenue pools and filings behind the plant vaccine estimate

The report uses 2025 as the base year and forecasts to 2035, with CAGR calculated over 2025–2035. Market values come from Credence Research's market model, built from separate estimates of product sales, contract service fees and funded program spending for each active plant platform, and checked against securities filings, Government of Canada notices and company announcements. Segment and regional splits are Credence Research estimates, while livestock context uses USDA Foreign Agricultural Service herd data.

Flu data and animal marker vaccines set the pace to 2035

Through 2035, plant-based vaccines will shift from development funding toward product revenue, but only if plant-made flu data hold and supply proves reliable. Credence Research expects VLP flu vaccines to drive most human revenue after 2030, while marker subunit vaccines expand in pig and poultry markets across Asia Pacific and Latin America. North America will grow fastest on the strength of the Canadian pipeline. The pace will depend on trial results, regulatory review and whether governments keep funding pandemic-ready plant capacity after 2030.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.